Biogen Inc.’s stock is trading at $131.52 on July 25th, with a trailing P/E of 13.00 and a forward P/E of 8.85. Despite challenges with the FDA over Aduhelm, the company continues to generate strong cash flows and has promising growth drivers like Leqembi. With acquisitions and a pipeline of Phase III candidates, Biogen is poised for growth. The healthcare sector’s low valuations and potential market sentiment shift could also benefit the company. Shares are trading in the $115–$130 range, offering an attractive risk/reward profile. Billionaire Ken Fisher also sees potential in BP p.l.c. (BP) as an energy stock to buy.

Read more at Yahoo Finance: Biogen Inc. (BIIB): A Bull Case Theory